Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

por Catenacci, D.V.T., Chung, H.C., Shen, L., Moehler, M., Yoon, H.H., Rosales, M.K., Kang, Y.-K.
Publicado 2021

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado 2021

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

por An, E., Ock, C.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Kim, T.-Y., Liao, W.-L., Cecchi, F., Blackler, A., Thyparambil, S., Kim, W. H., Burrows, J., Hembrough, T., Catenacci, D. V. T., Oh, D.-Y., Bang, Y.-J.
Publicado 2017

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

por Catenacci, D.V.T., Kang, Y.-K., Yoon, H.H., Shim, B.Y., Kim, S.T., Oh, D.-Y., Spira, A.I., Ulahannan, S.V., Avery, E.J., Boland, P.M., Chao, J., Chung, H.C., Gardner, F., Klempner, S.J., Lee, K.-W., Oh, S.C., Peguero, J., Sonbol, M.B., Shen, L., Moehler, M., Sun, J., Li, D., Rosales, M.K., Park, H.
Publicado 2022